GLP-1 drug measurably slows biological aging
A widely used weight-loss drug does more than shed pounds. Researchers found that semaglutide also slows biological aging, as measured by chemical marks on DNA.
Semaglutide is a GLP-1 receptor agonist: a drug that signals fullness to the brain and thereby reduces calorie intake. In a clinical trial involving 108 adults with HIV-associated abdominal fat accumulation, participants received weekly injections of semaglutide or placebo for 32 weeks. The researchers used epigenetic clocks to measure biological aging. These clocks read chemical tags on DNA (DNA methylation) that shift as we grow older.
Nine percent slower biological aging
Participants who received semaglutide aged biologically about 9% more slowly, as measured by the DunedinPACE clock. A second clock, PCGrimAge, showed that processes linked to all-cause mortality risk also slowed significantly. The effect appeared broadly across clocks measuring aging in blood, brain, heart, kidneys, liver, and metabolism.
The researchers suggest several mechanisms. First, semaglutide reduces visceral fat (abdominal fat around organs) that releases inflammatory signals. Second, the drug lowers chronic immune activation, a state in which the immune system remains persistently and mildly active. Both processes are tentatively considered accelerators of biological aging.
Losing visceral fat is the key factor
One important caveat: the researchers argue that these effects likely stem largely from weight loss itself, not from semaglutide specifically. Anyone who loses visceral fat through dieting would probably see similar changes in epigenetic clocks. The study primarily confirms how damaging excess visceral fat is to biological age. From a longevity perspective, it is notable that weight loss through this route is now measurably visible in aging clocks, though the study itself does not centre that interpretation.
The findings were published via the University of California San Diego.